Adverse drug events in hospitalized patients with chronic kidney disease

International Journal of Clinical Pharmacology and Therapeutics

Volumn 48, Issue 9, 2010, Pages 571-576

  Hassan, Y ^a   Al Ramahi, R J ^b   Aziz, N A ^a   Ghazali, R ^c  

^a SCHOOL OF PHARMACEUTICAL SCIENCES   (Malaysia)

^b AN NAJAH NATIONAL UNIVERSITY   (Palestine)

^c Penang Adventist Hospital   (Malaysia)

Author keywords

Adverse drug events; CKD; Patient safety; Preventability; Type

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIINFECTIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CORTICOSTEROID; DIURETIC AGENT; MINERAL; RENIN INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; DRUG MONITORING; DRUG SAFETY; DRUG USE; ENDOCRINE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GENERAL HOSPITAL; HEMATOLOGIC DISEASE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; KIDNEY DISEASE; LABORATORY TEST; LIVER DISEASE; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MEDICAL ASSESSMENT; MEDICAL RECORD REVIEW; MEDICATION ERROR; METABOLIC DISORDER; NEUROMUSCULAR DISEASE; PATIENT SAFETY; PHARMACEUTICAL CARE; PHARMACIST; PHYSICAL EXAMINATION; PROBABILITY; RESPIRATORY TRACT DISEASE; SKIN DISEASE; UNSPECIFIED SIDE EFFECT; AGED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; HOSPITALIZATION; KIDNEY FAILURE, CHRONIC; MIDDLE AGED;

ADULT; AGED; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FEMALE; HOSPITALIZATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED;

EID: 77956917630     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP48571     Document Type: Article

References (29)

1. Classen DC, Pestotnik SL, Evans RS et al. Adverse drug events in hospitalized patients: excessive length of stay, extra cost, and attributable mortality. JAMA. 1997; 227: 301-306.
2. BatesDW, Spell N, Cullen DJ et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA. 1997; 277: 307-311.
3. Primohamed M, James S, Meakin S et al. Adverse drug reactions as a cause of admission to hospital: prospective analysis of 18 820 patients. BMJ. 2004; 329: 15-19. (Pubitemid 38869995)
4. Fattinger K, M Poos, P Vegeres et al. Epidemiology of drug exposure and adverse drug reactions in two Swiss departments of internal medicine. Brit J Clin Pharm. 2000; 49: 158-167.
5. Riedl MA, Casillas AM. Adverse drug reactions: types and treatment options. American Family Physician. 2003; 68: 1781-1790.
6. Fanikos J, Cina JL, Baroletti S et al. Adverse drug events in hospitalized cardiac patients. American Journal of Cardiology. 2007; 100: 1465-1469.
7. Ramesh M, Pandit J, Parthasarathi G. Adverse drug reactions in a south Indian hospital-their Severity and cost involved. Pharmacoepidemiol Drug Saf. 2003; 12: 687-692.
8. Lazarou J, Pomeranz BH, Corey PN. Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies. JAMA. 1998; 279: 1200-1205.
9. Pirmohamed M, Breckenridge AM, Kitteringham NR, Park BK. Fortnightly review: Adverse drug reactions. BMJ. 1998; 316: 1295-1298.
10. Gandhi TK, Weingart SN, Borus J et al. Adverse drug events in ambulatory care. N Engl J Med. 2003; 348: 1556-1164.
11. Kanjanarat P, Winterstein AG, Johns TE et al. Nature of preventable ADEs in hospitals: a literature review. Am J Health Syst Pharm. 2003; 60: 1750-1759.
12. Bates DW, Miller EB, Cullen DJ et al. Patient risk factors for adverse drug events in hospitalized patients. Arch Intern Med. 1999; 159: 2553-2560.
13. Corsonello A, Pedone C, Corica Fet al. Concealed Renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med. 2005; 165: 790-795.
14. Morimoto T, Gandhi TK, Seger AC at al. Adverse drug events and medication errors: detection and classification methods. Quality and Safety Health Care. 2004; 13: 306-314.
15. Gabardi S, Abramson S. Drug dosing in chronic kidney disease. Medical Clinic of North America. 2005; 89: 649-687.
16. Kappel J, Calissi P. Safe drug prescribing for patients with renal insufficiency. CMAJ. 2002; 166: 473-477.
17. Manley HJ, McClaran ML, Wright MA et al. Factors associated with medication-related problems in ambulatory hemodialysis patients.AmJ Kidney Dis. 2003; 41: 386-393.
18. Loghman-Adham M. Medication noncompliance in patients with chronic disease: issues in dialysis and renal transplantation.AmJ Manag Care. 2003; 9: 155-171.
19. Curtin RB, Svarstad BL, Keller TH. Hemodialysis patients' noncompliance with oral medications. ANNAJ. 1999; 26: 307-316; discussion 317, 335.
20. Manley HJ, Cannella CA, Bailie GR et al. Medication- related problems in ambulatory hemodialysis patients: A pooled analysis. Am J Kidney Dis. 2005; 46: 669-680.
21. Manley HJ, Drayer DK, Muther RS. Medicationrelated problem type and appearance rate in ambulatory hemodialysis patients. BMC Nephrology. 2003; 4: 10.
22. Nebeker JR, Barach P, Samore MH. Clarifying adverse drug events: a clinician's guide to terminology, documentation, and reporting. Ann Intern Med. 2004; 140: 795-801.
23. Nebeker JR, Hurdle JF, Hoffman JM et al. Developing a taxonomy for research in adverse drug events: potholes and signposts. Proc AMIASymp. 2001; 493-497.
24. Naranjo C, Busto U, SellersEMet al.Amethod for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981; 30: 239-245.
25. Rommers MK, Teepe-Twiss IM, Guchelaar HG. Preventing adverse drug events in hospital practice: an overview. Pharmacoepidemiol Drug Saf. 2007; 16: 1129-1135.
26. Leape LL, BatesDW, Cullen DJ et al. System analysis of adverse drug events. JAMA. 1995; 274: 35-43.
27. Leape LL, Cullen DJ, Clapp MD et al. Pharmacist participation on physician rounds and adverse drug events in the intensive care unit. JAMA. 1999; 282: 267-270.
28. Kucukarslan SN, Peters M, Mlynarek MM et al. Pharmacists on rounding teams reduce preventable adverse drug events in hospital general medicine units. Arch Intern Med. 2003; 163: 2014-2018.
29. Manley HJ, Carroll CA. The clinical and economic impact of pharmaceutical care in end stage renal disease patients. Semin Dial. 2002; 15: 45-49.